Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Kansas City, Kansas 66160


RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of indole-3-carbinol may prevent cancer. PURPOSE: This randomized phase I trial is studying the side effects and best dose of indole-3-carbinol and to see how well it works compared to placebo in preventing cancer in healthy participants.

Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose of indole-3-carbinol in healthy participants. - Determine the safety and tolerability of this drug in these participants. - Determine the pharmacokinetics of this drug in these participants. Secondary - Determine the effects of this drug on selected markers of sexual function in these participants. - Determine the effects of this drug on markers of susceptibility to cancer in these participants. OUTLINE: This is a randomized, double-blind, placebo-controlled, dose-escalation study. Participants at each dose level are randomized to 1 of 2 treatment arms. - Arm I: Participants receive a single dose of oral indole-3-carbinol on day 1. - Arm II: Participants receive a single dose of oral placebo on day 1. Cohorts of 3 participants receive escalating doses of indole-3-carbinol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 participants experiences dose-limiting toxicity. An additional cohort of 3 participants is treated at the MTD. Participants are followed on days 2, 3, and 6. PROJECTED ACCRUAL: A total of 24 participants (18 in arm I and 6 in arm II) will be accrued for this study.


DISEASE CHARACTERISTICS: - Healthy participants - Non-smoker - No drug abuse, as determined by urine cotinine and baseline drug screen PATIENT CHARACTERISTICS: Age - 18 to 70 Performance status - Not specified Life expectancy - At least 12 months Hematopoietic - Absolute granulocyte count > 1,500/mm^3 - Hemoglobin > 10 g/dL Hepatic - Bilirubin < 1.8 mg/dL - AST and ALT < 110 U/L - Alkaline phosphatase < 300 U/L Renal - Creatinine < 2.0 mg/dL - Albumin > 3.0 g/dL Pulmonary - No asthma Other - Not pregnant or nursing - Negative pregnancy test - Weight within 20% of ideal body weight by the Metropolitan Life table - No serious drug allergies - No arthritis - No acute, unstable, chronic, or recurring medical condition - No strict vegetarians - No diabetes - No evidence of an active malignancy - No other serious intolerance or allergies - Mild seasonal allergies allowed - No other serious acute or chronic illness - None of the following chronic conditions: - Headaches - Dysphoria - Fatigue - Dizziness - Blurred vision - Insomnia - Rhinorrhea - Nausea - Vomiting - Abdominal pain - Diarrhea - Constipation - Premenstrual syndrome - Cessation of menses within the past 10 days (menstruating women only) PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Concurrent oral contraceptives allowed Radiotherapy - Not specified Surgery - Not specified Other - More than 21 days since prior medications, herbal products, dietary supplements, or high-dose vitamins - More than 3 months since prior investigational drugs - At least 14 days since prior and no concurrent ingestion of cruciferous vegetables, including any of the following: - Broccoli - Cabbage, including coleslaw - Cauliflower - Bok-choy - Brussels sprouts - Collards - Kale - Kohlrabi - Mustard greens - Rutabaga - Turnip - Watercress - At least 7 days since prior and no concurrent alcohol consumption - At least 48 hours since prior ingestion of grapefruit-containing foods and beverages - No concurrent chronic drug therapy - No other concurrent supplements, including dietary supplements, vitamins, herbal products, or over-the-counter medications

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Indole-3-Carbinol in Preventing Cancer in Healthy Participants

Official Title:

Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-Indolymethane (DIM) Nutritional Product

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

70 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Cancer Institute (NCI)

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Masking: Double-Blind, P

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Gregory Reed, PhD
Principal Investigator
University of Kansas

Study Dates

Start Date:November 2004
Verification Date:May 2006
Last Changed Date:July 23, 2008
First Received Date:January 7, 2005

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:University of Kansas
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.